Dynavax Technologies Corporation (DVAX)
USD 10.39
(-2.44%)
USD 10.39
(-2.44%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 375.02 Million USD | -7.36% |
| 2022 | 404.83 Million USD | -50.44% |
| 2021 | 816.87 Million USD | 177.3% |
| 2020 | 294.57 Million USD | 8.79% |
| 2019 | 270.77 Million USD | 83.18% |
| 2018 | 147.81 Million USD | 668.45% |
| 2017 | 19.23 Million USD | -6.07% |
| 2016 | 20.47 Million USD | -30.71% |
| 2015 | 29.55 Million USD | -21.83% |
| 2014 | 37.8 Million USD | 106.29% |
| 2013 | 18.32 Million USD | -26.47% |
| 2012 | 24.92 Million USD | -27.16% |
| 2011 | 34.22 Million USD | 6.48% |
| 2010 | 32.13 Million USD | -27.11% |
| 2009 | 44.09 Million USD | -40.79% |
| 2008 | 74.46 Million USD | -8.42% |
| 2007 | 81.31 Million USD | 241.41% |
| 2006 | 23.81 Million USD | 315.67% |
| 2005 | 5.73 Million USD | -58.39% |
| 2004 | 13.77 Million USD | -84.49% |
| 2003 | 88.78 Million USD | 1.06% |
| 2002 | 87.84 Million USD | 77.35% |
| 2001 | 49.53 Million USD | 4.09% |
| 2000 | 47.58 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 368.08 Million USD | -1.85% |
| 2024 Q2 | 373.47 Million USD | 1.46% |
| 2023 Q3 | 368.01 Million USD | 2.45% |
| 2023 Q4 | 375.02 Million USD | 1.9% |
| 2023 Q2 | 359.22 Million USD | -11.56% |
| 2023 FY | 375.02 Million USD | -7.36% |
| 2023 Q1 | 406.19 Million USD | 0.33% |
| 2022 Q1 | 721.49 Million USD | -11.68% |
| 2022 Q3 | 498.76 Million USD | -16.9% |
| 2022 Q4 | 404.83 Million USD | -18.83% |
| 2022 Q2 | 600.2 Million USD | -16.81% |
| 2022 FY | 404.83 Million USD | -50.44% |
| 2021 Q2 | 564.52 Million USD | 44.62% |
| 2021 FY | 816.87 Million USD | 177.3% |
| 2021 Q1 | 390.35 Million USD | 32.51% |
| 2021 Q4 | 816.87 Million USD | -4.14% |
| 2021 Q3 | 852.13 Million USD | 50.95% |
| 2020 Q1 | 247.43 Million USD | -8.62% |
| 2020 Q4 | 294.57 Million USD | 3.68% |
| 2020 Q2 | 271.01 Million USD | 9.53% |
| 2020 Q3 | 284.11 Million USD | 4.83% |
| 2020 FY | 294.57 Million USD | 8.79% |
| 2019 Q3 | 261.85 Million USD | 2.09% |
| 2019 FY | 270.77 Million USD | 83.18% |
| 2019 Q1 | 253.44 Million USD | 71.45% |
| 2019 Q2 | 256.49 Million USD | 1.2% |
| 2019 Q4 | 270.77 Million USD | 3.41% |
| 2018 Q4 | 147.81 Million USD | 6.06% |
| 2018 Q2 | 132.55 Million USD | 2.4% |
| 2018 Q1 | 129.44 Million USD | 572.94% |
| 2018 FY | 147.81 Million USD | 668.45% |
| 2018 Q3 | 139.37 Million USD | 5.15% |
| 2017 Q4 | 19.23 Million USD | 43.63% |
| 2017 Q3 | 13.39 Million USD | 17.06% |
| 2017 Q2 | 11.44 Million USD | -10.17% |
| 2017 Q1 | 12.73 Million USD | -37.81% |
| 2017 FY | 19.23 Million USD | -6.07% |
| 2016 Q1 | 25.21 Million USD | -14.69% |
| 2016 FY | 20.47 Million USD | -30.71% |
| 2016 Q2 | 28.84 Million USD | 14.4% |
| 2016 Q3 | 31.02 Million USD | 7.57% |
| 2016 Q4 | 20.47 Million USD | -33.99% |
| 2015 Q1 | 37.09 Million USD | -1.88% |
| 2015 Q4 | 29.55 Million USD | 6.62% |
| 2015 FY | 29.55 Million USD | -21.83% |
| 2015 Q3 | 27.71 Million USD | -20.73% |
| 2015 Q2 | 34.96 Million USD | -5.74% |
| 2014 Q3 | 25.32 Million USD | 11.08% |
| 2014 Q4 | 37.8 Million USD | 49.32% |
| 2014 FY | 37.8 Million USD | 106.29% |
| 2014 Q1 | 19.73 Million USD | 7.66% |
| 2014 Q2 | 22.79 Million USD | 15.52% |
| 2013 Q1 | 21.69 Million USD | -12.97% |
| 2013 Q3 | 19.3 Million USD | -0.26% |
| 2013 Q4 | 18.32 Million USD | -5.05% |
| 2013 FY | 18.32 Million USD | -26.47% |
| 2013 Q2 | 19.35 Million USD | -10.79% |
| 2012 Q2 | 31.18 Million USD | -3.44% |
| 2012 Q3 | 34.76 Million USD | 11.47% |
| 2012 Q4 | 24.92 Million USD | -28.3% |
| 2012 Q1 | 32.29 Million USD | -5.63% |
| 2012 FY | 24.92 Million USD | -27.16% |
| 2011 Q3 | 28.49 Million USD | -0.38% |
| 2011 FY | 34.22 Million USD | 6.48% |
| 2011 Q1 | 29.01 Million USD | -9.73% |
| 2011 Q2 | 28.6 Million USD | -1.42% |
| 2011 Q4 | 34.22 Million USD | 20.12% |
| 2010 FY | 32.13 Million USD | -27.11% |
| 2010 Q2 | 58.87 Million USD | 27.75% |
| 2010 Q1 | 46.08 Million USD | 4.51% |
| 2010 Q3 | 38.58 Million USD | -34.46% |
| 2010 Q4 | 32.13 Million USD | -16.7% |
| 2009 Q1 | 57.78 Million USD | -22.41% |
| 2009 FY | 44.09 Million USD | -40.79% |
| 2009 Q4 | 44.09 Million USD | -0.06% |
| 2009 Q3 | 44.12 Million USD | -0.94% |
| 2009 Q2 | 44.54 Million USD | -22.91% |
| 2008 FY | 74.46 Million USD | -8.42% |
| 2008 Q3 | 74.18 Million USD | -4.69% |
| 2008 Q4 | 74.46 Million USD | 0.38% |
| 2008 Q2 | 77.83 Million USD | -1.83% |
| 2008 Q1 | 79.29 Million USD | -2.49% |
| 2007 Q4 | 81.31 Million USD | 91.63% |
| 2007 FY | 81.31 Million USD | 241.41% |
| 2007 Q2 | 38.67 Million USD | 74.2% |
| 2007 Q1 | 22.19 Million USD | -6.8% |
| 2007 Q3 | 42.43 Million USD | 9.73% |
| 2006 Q1 | 6.52 Million USD | 13.87% |
| 2006 Q4 | 23.81 Million USD | 10.27% |
| 2006 FY | 23.81 Million USD | 315.67% |
| 2006 Q3 | 21.6 Million USD | 151.37% |
| 2006 Q2 | 8.59 Million USD | 31.69% |
| 2005 FY | 5.73 Million USD | -58.39% |
| 2005 Q4 | 5.73 Million USD | -19.57% |
| 2005 Q3 | 7.12 Million USD | -0.9% |
| 2005 Q2 | 7.18 Million USD | 20.64% |
| 2005 Q1 | 5.95 Million USD | -56.72% |
| 2004 Q1 | 14.11 Million USD | -84.1% |
| 2004 FY | 13.77 Million USD | -84.49% |
| 2004 Q2 | 13.64 Million USD | -3.32% |
| 2004 Q3 | 8.69 Million USD | -36.29% |
| 2004 Q4 | 13.77 Million USD | 58.39% |
| 2003 FY | 88.78 Million USD | 1.06% |
| 2003 Q4 | 88.78 Million USD | 0.0% |
| 2002 FY | 87.84 Million USD | 77.35% |
| 2001 FY | 49.53 Million USD | 4.09% |
| 2000 FY | 47.58 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 60.435% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -3977.85% |
| Embecta Corp. | 2.03 Billion USD | 81.581% |
| Pacira BioSciences, Inc. | 704.25 Million USD | 46.749% |
| PainReform Ltd. | 2.69 Million USD | -13836.232% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -6008.281% |
| SCYNEXIS, Inc. | 55.45 Million USD | -576.328% |
| Journey Medical Corporation | 56.49 Million USD | -563.771% |
| Safety Shot Inc | 3.89 Million USD | -9535.657% |
| Alpha Teknova, Inc. | 38.55 Million USD | -872.8% |
| Bright Green Corporation | 6.43 Million USD | -5725.071% |
| Procaps Group, S.A. | 462.06 Million USD | 18.837% |
| Alvotech | 1.88 Billion USD | 80.079% |
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | 20.491% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | -128.806% |
| Cosmos Health Inc. | 30.25 Million USD | -1139.645% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 43.246% |
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | -173.998% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -6008.281% |
| Theratechnologies Inc. | 98.63 Million USD | -280.199% |
| Harrow Health, Inc. | 241.75 Million USD | -55.127% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -4183.052% |
| Biofrontera Inc. | 23.13 Million USD | -1520.744% |
| DURECT Corporation | 30.4 Million USD | -1133.388% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 23.066% |
| Cronos Group Inc. | 43.73 Million USD | -757.47% |
| OptiNose, Inc. | 194.33 Million USD | -92.978% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 54.118% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -674.123% |
| RedHill Biopharma Ltd. | 20.97 Million USD | -1687.691% |
| Organogenesis Holdings Inc. | 181.36 Million USD | -106.782% |
| Guardion Health Sciences, Inc. | 3.77 Million USD | -9841.959% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | -614.111% |
| Radius Health, Inc. | 804.29 Million USD | 53.372% |
| Universe Pharmaceuticals INC | 13.75 Million USD | -2626.588% |
| ProPhase Labs, Inc. | 42.54 Million USD | -781.497% |
| Phibro Animal Health Corporation | 725.54 Million USD | 48.311% |
| Procaps Group S.A. | 462.06 Million USD | 18.837% |
| TherapeuticsMD, Inc. | 14.02 Million USD | -2574.54% |
| Viatris Inc. | 27.21 Billion USD | 98.622% |
| Rockwell Medical, Inc. | 30.88 Million USD | -1114.377% |
| Aytu BioPharma, Inc. | 90.37 Million USD | -314.946% |
| SIGA Technologies, Inc. | 57.97 Million USD | -546.846% |
| Tilray Brands, Inc. | 892.11 Million USD | 57.962% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | -70.621% |
| Shineco, Inc. | 47.6 Million USD | -687.838% |
| PetIQ, Inc. | 645.22 Million USD | 41.877% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -170744.419% |
| Incannex Healthcare Limited | 5.83 Million USD | -6332.659% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 63.211% |
| Alimera Sciences, Inc. | 107.35 Million USD | -249.334% |
| Silver Spike Investment Corp. | 3 Million USD | -12359.969% |
| Assertio Holdings, Inc. | 148.41 Million USD | -152.684% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -19680.112% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | -1659.373% |
| Clever Leaves Holdings Inc. | 7.02 Million USD | -5237.66% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -4316.968% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | -116.293% |
| Hempacco Co., Inc. | 18.82 Million USD | -1892.434% |
| Talphera, Inc. | 6.29 Million USD | -5862.226% |
| Alvotech | 1.88 Billion USD | 80.079% |
| Eagle Pharmaceuticals, Inc. | 172.6 Million USD | -117.279% |
| Lantheus Holdings, Inc. | 835.25 Million USD | 55.101% |
| Currenc Group, Inc. | 177.67 Million USD | -111.072% |
| Kamada Ltd. | 109.96 Million USD | -241.029% |
| Indivior PLC | 1.95 Billion USD | 80.78% |
| Evoke Pharma, Inc. | 9.64 Million USD | -3787.031% |
| Flora Growth Corp. | 17.22 Million USD | -2077.587% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -4316.968% |
| Evolus, Inc. | 209.68 Million USD | -78.849% |
| HUTCHMED (China) Limited | 536.38 Million USD | 30.083% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 57.066% |
| Akanda Corp. | 12.66 Million USD | -2860.197% |